Loading...
Allogeneic stem cell transplantation (AlloSCT) with hematopoietic stem cells derived from donor peripheral blood (PB) or bone marrow is a curative option for patients with high-risk or relapsed hematologic malignancies, but procedure-related morbidity and mortality may be increased in the years following the procedure. A retrospective cohort study is now reported from three U.S. transplant centers, assessing outcomes for AlloSCT patients who survived 2 years or more following the procedure, performed from 1974 through 2014. The investigators assessed all-cause disease recurrence- and non–recurrence-related mortality. The latter included deaths from infections, second primary malignancies, and cardiopulmonary disease.
Among the 4741 patients,…